Artivion (NYSE:AORT) EVP Sells $238,618.48 in Stock

Artivion, Inc. (NYSE:AORT) EVP Lance Berry sold 6,316 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total value of $238,618.48. Following the completion of the sale, the executive vice president owned 210,827 shares in the company, valued at approximately $7,965,044.06. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Artivion Trading Down 1.8%

Shares of Artivion stock opened at $37.18 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The business has a fifty day simple moving average of $41.06 and a two-hundred day simple moving average of $42.84. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.25. The company has a market capitalization of $1.78 billion, a price-to-earnings ratio of 185.91 and a beta of 1.60.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. Research analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on AORT. Canaccord Genuity Group lowered their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Wall Street Zen cut Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Stifel Nicolaus set a $55.00 target price on Artivion in a research report on Thursday. Oppenheimer reiterated an “outperform” rating and set a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Finally, Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $50.47.

Hedge Funds Weigh In On Artivion

Hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in Artivion in the 2nd quarter valued at about $664,000. Kennedy Capital Management LLC grew its position in shares of Artivion by 20.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 367,762 shares of the company’s stock worth $11,437,000 after purchasing an additional 63,205 shares in the last quarter. Sio Capital Management LLC increased its holdings in shares of Artivion by 31.0% during the second quarter. Sio Capital Management LLC now owns 158,736 shares of the company’s stock worth $4,937,000 after purchasing an additional 37,558 shares during the period. Atria Investments Inc acquired a new stake in shares of Artivion in the second quarter valued at approximately $244,000. Finally, Osterweis Capital Management Inc. acquired a new stake in shares of Artivion in the second quarter valued at approximately $3,750,000. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.